BioStock: Elicera teams up with China Medical University for cancer study

Elicera Therapeutics has announced a new research collaboration with the Fourth Affiliated Hospital of China Medical University to assess the efficacy of oncolytic virus ELC-201 in preclinical proof-of-concept studies. This collaboration will explore the potential of ELC-201 across various solid tumour indications. BioStock turned to Elicera’s CEO Jamal El-Mosleh to learn more.

Read the article at biostock.se:

Elicera teams up with China Medical University for cancer study - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/